Compare Eli Lilly And Co (LLY) vs S&P Global Inc (SPGI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs S&P Global Inc — how do they compare? Eli Lilly And Co trades at $1,176.32 (market cap $1.04T), while S&P Global Inc trades at $408.1 (market cap $118.72B). The key difference: Eli Lilly And Co is far larger — about 8.8× S&P Global Inc's market cap, and S&P Global Inc pays the higher dividend (0.96%). Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and S&P Global Inc for 123 Days on average.
| LLY | SPGI | |
|---|---|---|
Market Cap | $1.04T | $118.72B |
Volume | 3,064,878 | 1,647,917 |
Sector | Health | Financials |
52-Week High | $1.28K | $517.92 |
52-Week Low | $799.57 | $370.42 |
Typical Hold Time | 93 Days | 123 Days |
Enterprise Value | $1.09T | $130.21B |
Dividend Yield | 0.59% | 0.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,176.69, down 1.01% on the day, amid a bullish technical outlook and strong fundamental performance. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 consensus. Revenue surged to $65.18B in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing growth prospects.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include elevated valuation multiples and competitive pressures in the pharmaceutical sector. With a consensus price target of $1,350, upside potential exists, but investors should weigh execution risks against the company's innovation pipeline.
S&P Global (SPGI) trades at $406.06, up 2.75% today, with strong analyst support (85.7% buy ratings) and a consensus price target of $509.50. The stock shows robust fundamentals, including 30.54% net income margin and consistent revenue growth, though technical indicators signal near-term bearish pressure. Recent developments include expansion into digital asset risk assessment and AI-driven growth initiatives, positioning the company for future revenue streams.
Outlook remains positive due to high profitability, strategic acquisitions, and dominant market position, but risks include competitive pressures and macroeconomic sensitivity. The stock offers upside based on analyst targets, supported by stable cash flows and dividend payments, making it a compelling hold for long-term investors despite technical headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About S&P Global Inc
S&P Global provides data and benchmarks to capital and commodity market participants. In 2021 and excluding IHS Markit, S&P Ratings was over 45% of the firm's revenue and over 55% of the firm's operating income. S&P Ratings is the largest credit rating agency in the world. The firm's other segments include Market Intelligence, Indices, and Platts. Market Intelligence provides desktop tools and other data solutions to investment banks, corporations, and other entities. Indices provides benchmarks for financial markets and is monetized through subscriptions, asset-based fees, and transaction-based royalties. Platts provides benchmarks to commodity markets, principally petroleum.
Read more on SPGI →
